These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 15131062)

  • 1. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
    Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
    Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
    Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB
    Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
    Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC
    Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
    Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
    Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
    Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
    Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
    Berenson JR; Ma HM; Vescio R
    Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival.
    Zheng B; Fiumara P; Li YV; Georgakis G; Snell V; Younes M; Vauthey JN; Carbone A; Younes A
    Blood; 2003 Aug; 102(3):1019-27. PubMed ID: 12689928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
    Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR
    Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
    Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
    Yin D; Zhou H; Kumagai T; Liu G; Ong JM; Black KL; Koeffler HP
    Oncogene; 2005 Jan; 24(3):344-54. PubMed ID: 15531918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells.
    Izban KF; Ergin M; Huang Q; Qin JZ; Martinez RL; Schnitzer B; Ni H; Nickoloff BJ; Alkan S
    Mod Pathol; 2001 Apr; 14(4):297-310. PubMed ID: 11301346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
    Secchiero P; Milani D; Gonelli A; Melloni E; Campioni D; Gibellini D; Capitani S; Zauli G
    J Leukoc Biol; 2003 Aug; 74(2):223-32. PubMed ID: 12885939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
    Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
    Tan C; Waldmann TA
    Cancer Res; 2002 Feb; 62(4):1083-6. PubMed ID: 11861386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells.
    Franco AV; Zhang XD; Van Berkel E; Sanders JE; Zhang XY; Thomas WD; Nguyen T; Hersey P
    J Immunol; 2001 May; 166(9):5337-45. PubMed ID: 11313369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
    Khanbolooki S; Nawrocki ST; Arumugam T; Andtbacka R; Pino MS; Kurzrock R; Logsdon CD; Abbruzzese JL; McConkey DJ
    Mol Cancer Ther; 2006 Sep; 5(9):2251-60. PubMed ID: 16985059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
    Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R
    Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
    Cusack JC; Liu R; Houston M; Abendroth K; Elliott PJ; Adams J; Baldwin AS
    Cancer Res; 2001 May; 61(9):3535-40. PubMed ID: 11325813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.